arsenic trioxide has been researched along with Bile Duct Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Chen, W; Jiang, Q; Li, Q; Miao, L; Tang, L; Wang, Y; Xu, S; Yang, Y; Zhang, W | 1 |
| Dai, H; Ling, S; Shan, Q; Song, P; Wei, X; Xie, H; Xu, X; Yang, F; Zheng, S; Zhou, L; Zhuo, J | 1 |
| Shao, C; Wu, X; Yang, J; Zhang, S; Zhong, F | 1 |
3 other study(ies) available for arsenic trioxide and Bile Duct Cancer
| Article | Year |
|---|---|
The ATO/miRNA-885-5p/MTPN axis induces reversal of drug-resistance in cholangiocarcinoma.
Topics: Antineoplastic Agents; Arsenic Trioxide; Bile Duct Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; MicroRNAs; Signal Transduction | 2021 |
Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1.
Topics: AMP-Activated Protein Kinases; Animals; Arsenic Trioxide; Arsenicals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Drug Synergism; Heterografts; Humans; Mechanistic Target of Rapamycin Complex 1; Metformin; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 6; Oxides; p38 Mitogen-Activated Protein Kinases; Signal Transduction | 2017 |
Arsenic trioxide inhibits cholangiocarcinoma cell growth and induces apoptosis.
Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cholangiocarcinoma; Flow Cytometry; Humans; Oxides; Signal Transduction | 2010 |